ROI-NJ, citybizlist, S&P Global, InvestorsHub, MarketScreener.com, and the Global Legal Chronicle report that Lowenstein client DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero Biopharmaceuticals Holdings, Inc., a privately held biopharmaceutical company focused on the development of its late stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. The Lowenstein deal team includes Michael J. Lerner, Steven M. Skolnick, Alan Wovsaniker, Kate Basmagian, Robert Bee, Justin Gindi, and Erica Perlmutter. View Lowenstein's news announcement about this transaction.
Relevant Insights
-
PROFESSIONALS | Lawyers
Access the profiles of the more than 350 Lowenstein Sandler lawyers who provide critical legal counsel to clients in virtually every sector of the global economy...
-
NEWS & INSIGHTS | Firm News
Discover the latest updates and developments about Lowenstein Sandler...
-
NEWS & INSIGHTS | Publications
Access our insightful thought leadership, including articles, client alerts, and blog posts...